HANOI Aug 2 (Reuters): Arcturus Therapeutics Holdings Inc has announced that its Vietnamese partner has received regulatory approval to start a clinical trial of its Covid-19 vaccine candidate in the South-East Asian country.
The partner Vinbiocare, a unit of Vietnam's biggest conglomerate Vingroup, has signed a deal for the domestic manufacturing rights to Arcturus' vaccines, including ARCT-154 that targets variants such as the fast-spreading Delta strain.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
